Drugs / COLONYVAQ-CRC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07328087 | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COLONYVAQ-CRC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07328087 ↗ |
| Modality | Vaccine | “personalized multi-peptide neoantigen vaccine” NCT07328087 ↗ |
| Route | Subcutaneous | “for subcutaneous injection into lymph node-rich regions” NCT07328087 ↗ |